Tas Faruk, Bilgin Elif, Karabulut Senem, Tastekin Didem, Duranyildiz Derya
Institute of Oncology, Istanbul University, Capa, Istanbul 34390, Turkey.
Mol Clin Oncol. 2016 Apr;4(4):655-659. doi: 10.3892/mco.2016.759. Epub 2016 Feb 2.
Fibronectin is an important component of the extracellular matrix and serves a role in the pathogenesis of multiple malignancies. The expression of fibronectin also affects the outcome for patients with cancer. The objective of the present study was to determine the clinical significance of the serum fibronectin levels in patients with gastric cancer. A total of 63 patients with a pathologically confirmed diagnosis of gastric cancer were enrolled into the present study. Serum fibronectin concentrations were determined by the solid-phase sandwich enzyme-linked immunosorbent assay method. Age and sex matched healthy controls (n=30) were included in the analysis. The median age at diagnosis was 62 years (range 28-82 years). The baseline serum fibronectin levels of the patients with gastric cancer were significantly higher compared with those in the control group (median values, 606, vs. 193 ng/ml; P<0.001). The known clinical variables, including the age of the patient, gender, site of lesion, histology, histological grade, stage of disease and serum tumor markers, including lactate dehydrogenase, carcinoembryonic antigen and cancer antigen 19.9, were not found to be correlated with serum fibronectin concentrations (P>0.05). In addition, no correlation was observed in serum fibronectin level and response to chemotherapy (P=0.12). Serum fibronectin concentration demonstrated no prognostic role on survival (P=0.43). In conclusion, the serum levels of fibronectin may have a good diagnostic marker in patients with gastric cancer. However, its predictive and prognostic values remain to be elucidated.
纤连蛋白是细胞外基质的重要组成部分，在多种恶性肿瘤的发病机制中发挥作用。纤连蛋白的表达也会影响癌症患者的预后。本研究的目的是确定胃癌患者血清纤连蛋白水平的临床意义。本研究共纳入63例经病理确诊的胃癌患者。采用固相夹心酶联免疫吸附测定法测定血清纤连蛋白浓度。分析中纳入了年龄和性别匹配的健康对照者（n = 30）。诊断时的中位年龄为62岁（范围28 - 82岁）。胃癌患者的基线血清纤连蛋白水平显著高于对照组（中位值分别为606和193 ng/ml；P < 0.001）。未发现已知的临床变量，包括患者年龄、性别、病变部位、组织学类型、组织学分级、疾病分期以及血清肿瘤标志物，如乳酸脱氢酶、癌胚抗原和癌抗原19.9，与血清纤连蛋白浓度相关（P > 0.05）。此外，血清纤连蛋白水平与化疗反应之间未观察到相关性（P = 0.12）。血清纤连蛋白浓度对生存无预后作用（P = 0.43）。总之，血清纤连蛋白水平可能是胃癌患者的一个良好诊断标志物。然而，其预测和预后价值仍有待阐明。
